Elite Pharmaceuticals, Inc.
ELTP
$0.5475
-$0.0074-1.33%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.88M | 17.00M | -10.89M | -11.04M | 615.80K |
| Total Depreciation and Amortization | 508.30K | 520.50K | 489.60K | 553.50K | 558.70K |
| Total Amortization of Deferred Charges | 3.50K | 3.50K | 3.50K | 3.50K | 3.50K |
| Total Other Non-Cash Items | 27.26M | -4.22M | 11.91M | 14.20M | 2.91M |
| Change in Net Operating Assets | -7.11M | -9.38M | -2.58M | -2.26M | -942.50K |
| Cash from Operations | 14.78M | 3.92M | -1.06M | 1.46M | 3.14M |
| Capital Expenditure | -218.20K | -754.10K | 0.00 | -92.40K | -778.50K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 0.00 | 110.00K | 15.30K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 0.00 | 0.00 | 0.00 | -900.00K |
| Cash from Investing | -218.20K | -754.10K | 0.00 | 17.60K | -1.66M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -4.13M | -156.30K | -193.10K | -320.70K | -174.90K |
| Issuance of Common Stock | -- | 19.30K | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -4.13M | -137.00K | -193.10K | -320.70K | -174.90K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 10.43M | 3.03M | -1.26M | 1.15M | 1.31M |